Argenx: Seronegative Approval and a Pipeline Ramp Set Up a New Growth Phase

Argenx delivered one of its strongest quarters to date, with product net sales reaching $1.5 billion, up 60% year-over-year and 17% sequentially. This marks the 18th consecutive quarter of growth—a cadence that few biotechs ever achieve. As CEO Karen Massey noted, “The team delivered one of our strongest quarters yet, marking our 18th consecutive quarter of growth.” — Karen Massey, Chief Executive Officer · 2026-07-23 The quarter’s headline was the approval of VYVGART for seronegative generalized myasthenia gravis (gMG), a label expansion that the company sees as transformational.

A Broadened Label Reshapes the MG Opportunity

The seronegative approval is not merely an incremental label change; it expands VYVGART’s addressable market by 11,000 patients and makes it the first and only therapy approved across all serotypes of gMG, including triple seronegative patients who previously had no approved option. Early feedback is striking. “Although we are only 10 weeks in, so it's still very early, the feedback is overwhelmingly positive.” — Sandrine Piret-Gerard, Chief Commercial Officer · 2026-07-23 Sandrine Piret-Gerard, Chief Commercialization Officer, highlighted that payers are rapidly covering the new population, with policies already in place for approximately 55% of U.S. commercial lives within 10 weeks of launch, and most plans removing serology testing requirements. The seronegative patients included in this expansion are seeing a halo effect across the entire gMG market, driving earlier and broader adoption. This mirrors the company’s prior success with the prefilled syringe (PFS) launch, which had a similar expansionist strategy. As Karen noted in a prior call, “we are confident about PFS driving significant volume growth both for MG and CIDP.” — Karen Massey, Chief Operating Officer · 2025-05-08 The seronegative approval is the next leg of that same playbook.

Rheumatology Entry and a Deepening Pipeline

Looking ahead, the company has two registrational readouts before year-end. The most anticipated is autoimmune myositis data, expected in Q3. This marks Argenx’s entry into rheumatology—a strategic move beyond neurology. Management has framed myositis as a potential blockbuster opportunity, with both inclusion-body myositis (IBM) and dermatomyositis (DM) being evaluated. “We're really looking forward to the readout in Q3, and we're on track.” — Karen Massey, Chief Executive Officer · 2026-07-23 The second readout is for empasiprubart in multifocal motor neuropathy (MMN), a head-to-head against IVIg, with non-inferiority and superiority testing. Empasiprubart also has a Phase III program in CIDP, positioning it as a complementary therapy to VYVGART in the same space.

Beyond these, Argenx continues to invest in next-generation FcRn molecules and novel biologics. ARGX-121, an IgA sweeper, is advancing toward Phase II with promising data showing ~90% IgA reduction within days. The company is also broadening its business development aperture, using its strong balance sheet to scout for novel biology and new mechanisms of action. As CEO Massey stated, “we are focused on immunology assets, but we are focused on diversifying our pipeline beyond FcRn.” — Karen Massey, Chief Executive Officer · 2026-07-23 This capital allocation strategy is supported by a cash position of $5.2 billion and an operating profit of $494 million in Q2.

One of these patients, Zack shared, "I cut off my computer and cried. Hope, this is finally real hope from the seronegative community."

Financial Discipline and Long-Term Vision

Argenx’s financial profile is strengthening: operating profit grew 146% year-over-year, and the company expects increasing operating margins and sustained cash generation. The company has been disciplined in capital allocation, balancing R&D investments across a broad pipeline while also considering external innovation. In a prior call, CFO Karl Gubitz noted, “we would expect to have broad access also for seronegative and ocular, and we can assume a similar price as MG, i.e., $225,000 the net benefit or a net price to argenx.” — Karl Gubitz, Chief Financial Officer · 2026-02-26 That pricing framework remains intact, and the seronegative launch is already following that playbook.

The company’s trajectory is clearly on an upward path, but the next few quarters will be critical. The myositis readout and MMN data could redefine the company’s growth runway, particularly if they open up new therapeutic areas. With 18 consecutive quarters of growth and multiple catalysts ahead, Argenx is demonstrating that its initial success in MG was not a one-off but the foundation for a durable, diversified immunology franchise. The market will be watching closely whether these upcoming data points translate into the next phase of blockbuster expansion.